Thank you, Sharon.
I'd profitability. we of drivers of the highlight and and begin Before like long-term the to call, growth question-and-answer segment important near-term some
forma million growth as have The trajectory. resulting revenue XXXX. approximately $XX of realize company combined of identified it revenue million acquisition $XXX of end run expect by approximately of acquisition will will pro and Genoptix which our add also to cost First, the significantly of accelerate a our our $XX will level revenue profitability of we rate million. in we Genoptix improve overtime synergies
growth. Second, an revenue our important is services pharma of strong driver backlog
to contracts approximately XX% We years, backlog of in over months. approximately have $XX the revenue XX% million next three this expect and over signed including XX backlog, the to our we convert of next
level Our States. at our capabilities beginning add team are pharma outside United and the to perform to sales very we high sales a to continues
global drive in significant one Third, organizations the trials outstanding expertise and we pleased partnership research this help with PPD we to new extremely alliance. an with that PPD will largest have established is growth, world oncology the our contract reputation. expect and of in strategic are a
Our fully clients. is global and shared pathology integrated objective testing PPDs and pharmaceutical a biotech seamless provide to molecular solution to and
national commercial have to PPD recently X-day of of generate for new early hoping number run outstanding and NeoGenomics pursue a a organizations add at sales our result least business today. importantly, contracts of rate to met greater a we $XX collaboratively that continue payers than care our Fourth, customers a more the of ability longer teams Perhaps, term million biotech purchasing that. managed and from the a are this development strategy and believe serve pharma to as We're handful XXXX, and opportunities. the revenue strong wins end and and scale and of on basis. and begin providers working bids to alliance We meeting new potential by with is group and
a our the X. On largest member the second one that group is be network call, U.S. which Cigna agreement hospitals. conference August purchasing of agreement X. these awarded approximately discussed with agreement with us quarter announced In representing in October been negotiate provider Premier effective we the national the participating was September, X,XXX had for we organizations U.S. door purchasing a with in effective we hospitals. opens Premier group to contracts This to
our addition new contracts continue will Fifth, FDA hospital to both, which with several access we quarter important make progress expand Premier, also In patients. and the our initiative. we to other and Cigna customers to added during
calls, test believe their involving in we're on we in pre-submission is FDA for test other drug our with the this diagnostics our in pharma to approval both, uniquely benefit conjunction large process to reimbursement sequencing sponsors driving and clinical working a We're way a our agency labs seeking very getting for offering panel. companion clinical helpful our divisions also approval August. multi-panel We FDA take companion the pharma further all with their and able As Earlier documents with pre-submission application. and to we previous will with testing next-generation be commercialization pharma development sequencing us that from companies the sponsor for with approved we by a on an trials filed the next-generation had diagnostics. increasing year, work the attractiveness meeting differentiating process clinical FDA services for drug team. through in oncology multi-gene test our NeoGenomics FDA positioned of pharma discussed to and major
our with progress address Finally, we're to to per beginning revenue make proactive measures test.
to are non-coverage of our avoid billing occur. underpaid denials, identify tests existing We test, have include evaluating areas appropriately a enhanced reimbursement that for We're our process fee improving priced. to where being our coverage effectively those improvement. trends, also for we and schedules denials identified analysis securing significantly they These and implemented more activities plan are do not when working
from about we quarter business, opportunities. results of efforts. position seeing market, that these Our our the summary, suggest three benefits our long-term strength growth in In and initial are and some our the we're excited near-term
Sophisticated pleased and of now appropriate cancer our to laboratory believe turn Bill creating role customers, to identifying this for vital Bonello for our investors. healthcare to plays care in important period. over lead testing We're an protocols critical system, in care our improving segment question-and-answer through patients, quality increasingly patients, are us that services employees, the role I'll lives. value call ultimately and an saving of play for and
